...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Term sheet and enterprise valuation

Fuzzy, 

You don't need a NASDAQ listing to have liquidity. I would rather get a larger buyout price for Zenith Epigenetics in the short term and get a cash payout and maybe get a Zenith capital Corp Nasdaq ipo after that. The AGM maybe just another rubber stamp from the BOD . I would love to be shocked with some major news but I doubt it 

Share
New Message
Please login to post a reply